Michael Cobb

2 weeks ago | bioprocessonline.com | Michael Cobb

By Michael Cobb The pharmaceutical industry places significant emphasis on guaranteeing the safety and efficacy of sterile medicinal products, a goal intrinsically linked to the integrity of their container closure systems. For contract manufacturers, the integration of comprehensive Container Closure Integrity (CCI) strategies is not merely a regulatory requirement but a fundamental necessity for preserving drug product quality.

3 weeks ago | fedequipblog.fedequip.com | Michael Cobb

We will be attending CannaOne from June 12-13, 2025 at the Las Vegas Convention Center in Las Vegas, NV. Federal Equipment Company offers the largest selection of used growing & extraction equipment in the world for cultivation, hemp processing, botanical oils and more.

3 weeks ago | fedequipblog.fedequip.com | Michael Cobb

INTERPHEX 2025 is the premier global event for the pharmaceutical and biotechnology industries, bringing together industry professionals, exhibitors, and regulatory experts at the Javits Center in New York City from April 1-3, 2025. As a leader in advanced manufacturing and bioprocessing solutions, INTERPHEX fosters partnerships, showcases innovative solutions, and delivers valuable insights into the latest advancements in drug development, biopharmaceutical production, and automation.

4 weeks ago | fedequipblog.fedequip.com | Michael Cobb

Don’t miss our newest auction from Federal Equipment Company featuring pharmaceutical packaging equipment from Kindeva. The auction takes place on May 6-7 2025.

4 weeks ago | fedequipblog.fedequip.com | Michael Cobb

Ensuring Container Closure Integrity (CCI) in contract manufacturing is essential to maintaining sterility, drug product safety, and compliance across the pharmaceutical industry. A robust CCI strategy helps prevent microbial ingress, leakage, and stability failures, safeguarding parenteral products, biologics, and sterile injectable therapies throughout the product lifecycle.